

ASCO Annual Meeting, June 3-7, 2022

Presentation Schedule for Winship Cancer Institute of Emory University Faculty, Staff and Residents

Note: All times are Eastern Time unless otherwise noted.



Friday, June 3

Location	Time	Session Type	Abstract #	Author	Title
Arie Crown Theater	2:15PM - 2:30PM	Education Session		Sunil S. Badve, MD (Panel Speaker)	Protein Profiling of Breast Cancer for Treatment Decisions
S100a	2:45PM - 3:00PM	Education Session		Judy Gichoya, MD, MS (Panel Speaker)	Bias and Ethical Issues in Artificial Intelligence
S100a	2:47PM - 2:57PM	Education Session		Melinda Yushak, MD, PhD (Panel Speaker)	Tebentafusp for Uveal Melanoma
S100bc	4:00PM - 4:15PM	Education Session		Olatunji B. Alese, MD (Chair)	Role of ctDNA in Adjuvant and Metastatic Therapy for Gastrointestinal Cancers
E450	3:12PM - 3:24PM	Oral Abstract Session	7504	Sharon M. Castellino, MD, MSc	Brentuximab vedotin and association with event-free survival (EFS) in children with newly diagnosed high-risk Hodgkin lymphoma (HL): A report from the Children's Oncology Group phase 3 study AHOD1331 (NCT 02166463).
S406	6:09PM	Oral Abstract Session	6008	Nabil F. Saba, MD, FACP	A phase II trial of pembrolizumab and cabozantinib in patients (pts) with recurrent metastatic head and neck squamous cell carcinoma (RMHNSCC).

Conquer Cancer Foundation Grants and Awards Ceremony and Reception

Hyatt Regency McCormick Place, Regency Ballroom	4:00PM - 6:00PM			Award recipients include: Research Professorship for Diversity and Inclusion in Breast Cancer Mylin A. Torres, MD Young Investigator Awards Ralph Millett, MD David C. Qian, MD, PhD Merit Award James Janopaul-Naylor, MD
---	-----------------	--	--	---

Saturday, June 4

Location	Time	Session Type	Abstract #	Author	Title
Hall A	9:00AM - 12:00PM	Poster Session	8059	Nisha Joseph, MD	Analysis of long-term outcomes in R-ISS stage 2 multiple myeloma with and without the presence of high-risk cytogenetics.
Hall A	9:00AM - 12:00PM	Poster Session	8061	Rujul H. Parikh, MD (HMO Fellow)	Updated survival with extended follow-up on patients with newly diagnosed multiple myeloma treated with lenalidomide, bortezomib, and dexamethasone (RVD) induction therapy and a risk-stratified maintenance approach.
Hall A	9:00AM - 12:00PM	Poster Session	8063	Dabedochukwu Obiekwe, MBBS	The impact of complex karyotype identified by conventional cytogenetics on survival outcomes of 1,000 patients with newly diagnosed myeloma (NDMM).
Hall A	9:00AM - 12:00PM	Poster Session	8062	Nisha Joseph, MD	Clinical features of patients with multiple myeloma harboring t(4;14) and impact on long-term survival.
Hall A	9:00AM - 12:00PM	Poster Session	8064	Shama Pirmohammed, BA	Prognostic impact of t(11;14) on PFS1 among patients with myeloma receiving triplet induction therapy.
Hall A	9:00AM - 12:00PM	Poster Session	4118	Lana Khalil, MD (Post Doctoral Fellow)	Impact of metformin on clinical outcomes in advanced hepatocellular carcinoma treated with immune checkpoint inhibitors.
Hall A	9:00AM - 12:00PM	Poster Session	4097	Shishir K. Maithe, MD, FACS	NEO-GAP: A phase II single-arm prospective feasibility study of neoadjuvant gemcitabine/cisplatin/nab-paclitaxel for resectable high-risk intrahepatic cholangiocarcinoma.
Hall A	2:15PM - 5:15PM	Poster Session	12091	Jill M. Binkley, PT, MSc, CLT (TurningPoint collaborator)	Racial disparity in breast cancer survivorship: Results of a qualitative research study to identify themes from a series of national healthcare provider live virtual forums.

Hall D-1	2:15PM	Oral Abstract Session		Kevin Kalinsky MD, MS	A randomized, phase II trial of fulvestrant or exemestane with or without ribociclib after progression on anti-estrogen therapy plus cyclin-dependent kinase 4/6 inhibition (CDK 4/6i) in patients (pts) with unresectable or hormone receptor-positive (HR+), HER2-negative metastatic breast cancer (MBC): MAINTAIN trial
Hall A	2:30PM - 5:30PM	Poster Session	1562	Anna Avinger	Improving first-in-human and window-of-opportunity informed consent forms through participant feedback.
Hall A	2:30PM - 5:30PM	Poster Session	1502	Xu Ji, PhD	Association between the Affordable Care Act Medicaid expansion and survival in young adults newly diagnosed with cancer.
Hall A	2:30PM - 5:30PM	Poster Session	12102	Xin Hu, PhD	Race differences in patient-reported symptoms and adherence to adjuvant endocrine therapy among women with early-stage, hormone receptor-positive breast cancer.
S406	3:39PM-3:51PM	Oral Abstract Session	11505	Thomas Cash, MD, MSc	Long-term outcomes in patients with localized Ewing sarcoma treated with interval-compressed chemotherapy: A long-term follow-up report from Children's Oncology Group study AEWS0031
E450	4:00PM - 5:30PM	Education Session		Jonathon B. Cohen, MD (Chair)	Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
S100a	4:15PM - 4:27PM	Oral Abstract Session	6506	Xu Ji, PhD	Changes in opioid prescription, potential misuse, and substance use disorder in pediatric cancer survivors following the 2016 CDC opioid prescribing guideline
S404	5:30PM - 7:30PM	Poster Discussion Session	12016	Tekiah McClary, BS	Accounting for the high enrollment of African Americans in Winship Cancer Institute's myeloma clinical trials.
E451	5:30PM - 7:30PM	Poster Discussion Session	8019	Sagar Lonial, MD, FACP	Synergistic effects of low-dose belantamab mafodotin in combination with a gamma-secretase inhibitor (nirogacestat) in patients with relapsed/refractory multiple myeloma (RRMM): DREAMM-5 study.

Winship ASCO Reception

The Westin Chicago
River North Riverbar
7:00PM - 9:00PM CDT

Sunday, June 5

Location	Time	Session Type	Abstract #	Author	Title
Hall A	9:00AM - 12:00PM	Poster Session	2070	James Janopaul-Naylor, MD	Impact of systemic therapy regimen on survival of PCNSL.
Hall A	9:00AM - 12:00PM	Poster Session	2604	Mehmet Akce, MD	A phase 1 multiple-ascending dose study to evaluate the safety and tolerability of XmAb23104 (PD-1 x ICOS) in subjects with selected advanced solid tumors (DUET-3).
Hall A	9:00AM - 12:00PM	Poster Session	TPS3157	R. Donald Harvey, PharmD, BCOP, FCCP	First-in-human, phase 1, open-label, dose-escalation, dose-expansion study of ADCT-901 as monotherapy in patients with select advanced solid tumors
S103	8:30AM	Education Session		Martha L. Arellano, MD (Speaker)	Training Program Directors' Breakfast: Reviewing and Selecting Applicants for Interviews
S406	11:12AM	Oral Abstract Session	8007	Ajay K. Nooka MD, MPH, FACP (Presenter)	Teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM): Updated efficacy and safety results from MajesTEC-1.
S406	11:36AM	Oral Abstract Session		Madhav V. Dhodapkar, MBBS (Discussant)	Engaging T Cells in the Midst of the COVID-19 Pandemic
S504	12:00PM - 12:15PM	Education Session		Bree Eaton, MD (Speaker)	Modifying Radiotherapy to Reduce Late Effects in Medulloblastoma
E450	12:45PM - 1:00PM	Education Session		Ajay K. Nooka, MD, MPH, FACP (Chair)	The Role of Measurable Residual Disease Testing in Myeloma in the Quest for Cure
Arie Crown Theater	12:57PM - 1:09PM	Oral Abstract Session		Kristin A. Higgins, MD (Discussant)	Optimizing Radiotherapy for Lung Cancer
E253b	5:30PM - 6:45PM	Ticketed Session		Mylin Torres, MD	Meet the Professors: How Bad Is the Bone? Learning a Focused Radiology Review and Physical Exam in Patients With Spinal Metastases

Monday, June 6

Location	Time	Session Type	Abstract #	Author	Title
Hall A	9:00AM - 12:00PM	Poster Session	1074	Jeffrey Aldrich, MD (HMO Fellow)	Real-world outcomes of Black women versus non-Hispanic White women with advanced triple-negative breast cancer treated with immune checkpoint inhibitors at an urban cancer center.
Hall A	9:00AM - 12:00PM	Poster Session	TPS1117	Kevin Kalinsky, MD	postMONARCH: A phase 3 study of abemaciclib plus fulvestrant versus placebo plus fulvestrant in patients with HR+, HER2-, metastatic breast cancer following progression on a CDK4 & 6 inhibitor and endocrine therapy.
Hall A	9:00AM - 12:00PM	Poster Session	TPS1122	Kevin Kalinsky, MD	Phase Ib/II study of BCL-2 inhibitor lisafoclax (APG-2575) safety and tolerability when administered alone or combined with a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor in patients with estrogen receptor-positive (ER+) breast cancer or advanced solid tumors.
Hall A	9:00AM - 12:00PM	Poster Session	10041	Kelly C. Goldsmith, MD	Phase I trial of lorlatinib in combination with topotecan/cyclophosphamide in children with ALK-driven refractory or relapsed neuroblastoma: A new approaches to neuroblastoma therapy consortium study.

Hall A	9:00AM - 12:00PM	Poster Session	TPS1127	Jane L. Meisel, MD	Phase 1b/2 study of ladiratumab vedotin (LV) in combination with pembrolizumab for first-line treatment of triple-negative breast cancer (SGNLVA-002, trial in progress).
Hall A	9:00AM - 12:00PM	Poster Session	TPS8603	Suresh Ramalingam, MD	Phase 2 study of tarlatamab, a DLL3-targeting, half life-extended, bispecific T-cell engager (HLE BiTE) immuno-oncology therapy, in relapsed/refractory small cell lung cancer (SCLC)
Hall A	9:00AM - 12:00PM	Poster Session	10038	Thomas Cash, MD, MSc	Phase I study of 131I-MIBG with dinutuximab for patients with relapsed or refractory neuroblastoma: A report from the new approaches to neuroblastoma therapy (NANT) consortium
Hall A	9:00AM - 12:00PM	Poster Session	9128	Madhusmita Behera, PhD	Molecular testing and patterns of treatment in patients with NSCLC: An IASLC analysis of ASCO CancerLinQ Discovery Data.
Hall A	9:00AM - 12:00PM	Poster Session	9017	Conor Steuer, MD	Efficacy and safety of patritumab deruxtecan (HER3-DXd) in advanced/metastatic non-small cell lung cancer (NSCLC) without EGFR-activating mutations.
Hall A	9:00AM - 12:00PM	Poster Session	9119	Jennifer Marks, MD	Analysis of MET exon 14 skipping mutations in non-small cell lung cancer (NSCLC) by histology and specific mutation.
Hall A	9:00AM - 12:00PM	Poster Session		Walid Shaib, MD (Chair)	Gastrointestinal Cancer—Colorectal and Anal
Hall D1	9:24AM	Special Session		Jonathan L. Kaufman, MD (Discussant)	Highlights of the Hematologic Malignancies - Plasma Cell Dyscrasia Track
E350	9:36AM - 9:48AM	Clinical Science Symposium		Olatunji B. Alese, MD (Discussant)	Exploring Barriers to Workplace Equity in Africa
S102	10:45AM	Case-Based Panel		Wendy Baer, MD (Moderator)	Loneliness: A Forgotten Challenge in Cancer Care
	2:15PM	Poster Session	6029	Nabil F. Saba, MD, FACP	CA209-9KY: Results of a phase II study of intensity modulated radiotherapy (IMRT) re-irradiation and concurrent/adjuvant nivolumab (nivo) in patients with loco-regionally recurrent or second primary (RSPT) head and neck squamous cell carcinoma (HNSCC).
E450	4:24 PM - 4:36 PM	Oral Abstract Session	1502	Xu Ji, PhD	Association between the Affordable Care Act Medicaid expansion and survival in young adults newly diagnosed with cancer.
E450	6:36PM - 6:48PM	Education Session		Ilana Graetz, PhD	Becoming a PRO: Improving Quality Through Digital Symptom Management

Online Posters

Location	Time	Session Type	Abstract #	Author	Title
Online	-	ePoster Session	e12529	Deepthi Kodali, MD	The impact of obesity on triple negative breast cancer (TNBC) outcomes at a diverse academic cancer center.
Online	-	ePoster Session	e15075	Lisa Sudmeier, MD, PhD	Dexamethasone and brain metastasis-infiltrating CD8+ T cells.
Online	-	ePoster Session	e16205	Tony Zhuang, MD	Telotristat ethyl with PRRT in the treatment of well differentiated neuroendocrine tumors.
Online	-	ePoster Session	e18591	Chloe Lalonde, MD	Comparison of sociodemographic characteristics of a phase 1 clinical trial population at an NCI-designated comprehensive cancer center in the Southeast to catchment area.
Online	-	ePoster Session	e18786	Xin Hu, PhD	The impact of vertical integration of oncologists on cancer outcomes and healthcare costs among metastatic prostate cancer patients.